Gastrointestinal involvement in patients with diabetes mellitus: Part II (second of two parts) - Diagnostic procedures, pharmacological and nonpharmacological therapy

Zeitschrift fur Gastroenterologie

Volumn 37, Issue 9, 1999, Pages 817-826

  Folwaczny, C ^a   Riepl, R ^b   Tschop M ^b   Landgraf, R ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Amylin; Cholecystokinin; Cisapride; Erythromycin; Glucagon like peptide; Octreotide; Prokinetic drugs; Proteinase inhibitor II

Indexed keywords

AMPICILLIN; AMYLIN; ANTIDIARRHEAL AGENT; CEPHALOSPORIN DERIVATIVE; CHOLECYSTOKININ; CIPROFLOXACIN; CISAPRIDE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; GLUCAGON LIKE PEPTIDE; LOPERAMIDE; METOCLOPRAMIDE; METRONIDAZOLE; PROKINETIC AGENT; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; SULPIRIDE; TETRACYCLINE;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFECT; DRUG MECHANISM; ESOPHAGUS PH; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL INFECTION; GASTROINTESTINAL RADIOGRAPHY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT SCINTISCANNING; GASTROINTESTINAL TRANSIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MANOMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PACEMAKER; PANCREAS TRANSPLANTATION; STOMACH PARESIS;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRANSIT; HUMANS; TREATMENT OUTCOME;

EID: 0032863366     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Klauser AG, Schindlbeck NE, Müller Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8
2. Folwaczny C, Hundegger K, Volger C et al. Measurement of transit disorders in different gastrointestinal segments of patients with diabetes mellitus in relation to duration and severity of the disease by use of the metal-detector test. Z Gastroenterol 1995; 33: 517-26
3. Folwaczny C, Voderholzer W, Riepl R et al. Clinical presentation, pathophysiology, diagnostic procederes and therapeutic strategies in progressive-systemic sclerosis (PSS) with gastrointestinal involvement. Z Gastroenterol 1996; 34: 497-508
4. Skinner DB, Booth DJ. Assessment of distal esophageal function in patients with hiatal hernia and- or gastroesophageal reflux. Ann Surg 1970; 172: 627-37
5. Horowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151-9
6. Tatsch K, Schroettle W, Kirsch CM. Multiple swallow test for the quantitative and qualitative evaluation of esophageal motility disorders. J Nucl Med 1991; 32: 1365-70
7. Tatsch K, Voderholzer WA, Weiss MJ et al. Simultaneous assessment of bolus transport and contraction parameters in mulitple-swallow investigations. J Nucl Med 1992; 33: 1291-300
8. Tothill P, McLoughlin GP, Heading RC. Techniques and errors in scintigraphic measurements of gastric emptying. J Nucl Med 1978; 19: 256-61
9. Beckers EJ, Leiper JB, Davidson J. Comparison of aspiration and scintigraphic techniques for the measurement of gastric emptying rates of liquids in humans. Gut 1992; 33: 115-7
10. Maughan RJ, Leiper JB. Methods for the assessment of gastric emptying in humans: An overview. Diabet Med 1996; 13: S6-10
11. 13C-octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: Validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996; 39: 823-30
12. Bolondi L, Bortolotti M, Santi V et al. Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology 1985; 89: 752-9
13. Holt S, Cervantes J, Wilkinson AA et al. Measurement of gastric emptying rate in humans by real-time ultrasound. Gastroenterology 1986; 90: 918-23
14. Ewe K, Press AG, Dederer W. Gastrointestinal transit of undigestible solids measured by metal detector EAS II. Eur J Clin Invest 1989; 19: 291-7
15. Beckers EJ, Rehrer NJ, Saris WH et al. Daily variation in gastric emptying when using the double sampling technique. Med Sci Sports Exerc 1991; 23: 1210-2
16. Sutton JA, Thompson S, Sobnack R. Measurement of gastric emptying rates by radioactive isotope scanning and epigastric impedance. Lancet 1985; 1: 898-900
17. Atanassova E, Daskalov I. Possibilities of the non-invasive electrogastrography. Acta Physiol Pharmacol Bulg 1995; 21: 105-11
18. Koch KL, Stern RM. Functional disorders of the stomach. Semin Gastrointest Dis 1996; 7: 185-95
19. Linz Z, Chen JD. Advances in time-frequency analysis of biomedical signals. Crit Rev Biomed Eng 1996; 24: 1-72
20. Lindberg C, Iwarzon M, Hammarlund B. 24-hour ambulatory electrogastrography in healthy volunteers. Scand J Gastroenterol 1996; 31: 658-64
21. Pfaffenbach B, Wegener M, Adamek RJ et al. Antral myoelectric activity, gastric emptying, and dyspeptic symptoms in diabetics. Scand J Gastroenterol 1995; 30: 1166-71
22. Schwizer W, Maecke H, Fried M. Measurement of gastric emptying by magnetic resonance imaging in humans. Gastroenterology 1992; 103: 369-76
23. Folwaczny C, Tschöp M, Riepl RL et al. Gastrointestinal involvement in patients with diabetes mellitus: Part 1 (first of two parts). Epidemiology, pathophysiology, clinical findings. Z Gastroenterol 1999; 37: 803-15
24. Wegener M, Borsch G, Schaffstein J et al. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8: 23-36
25. Dooley CP, el Newihi HM, Zeidler A et al. Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea. Scand J Gastroenterol 1988; 23: 217-23
26. Lautenbacher S, Galfe G, Haslbeck M et al. Studies on orocecal transit in diabetes mellitus. Med Klin 1990; 85: 291-301
27. Hinton JM, Lennard Jones JE et al. A new method for studying gut transit times using radioopaque markers. Gut 1969; 10: 842-7
28. Schindlbeck NE, Klauser AG, Müller-Lissner SA. Measurement of colon transit time. Z Gastroenterol 1990; 28: 399-404
29. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82
30. Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. Gastroenterology 1985; 88: 1973-9
31. Kronert K, Gotz V, Reuland P, Luft D et al. Gallbladder emptying in diabetic patients and control subjects assessed by real-time ultrasonography and cholescintigraphy: A methodological comparison. Ultrasound Med Biol 1989; 15: 535-9
32. Dodds WJ, Groth WJ, Darweesh RMA et al. Sonographic measurement of gallbladder volume. Am J Radiol 1985; 145: 1009-11
33. Kao CH, Tsou CT, Wang SJ et al. The evaluation of gallbladder function by quantitative radionuclide cholescintigraphy in patients with non-insulin dependent diabetes mellitus. Nucl Med Commun 1993; 14: 868-72
34. Stone BG, Gavaler JS, Belle SH et al. Impairement of gallbladder emptying in diabetes mellitus. Gastroenterology 1988; 95: 170-6
35. Ferrannini E. Gastrointestinal control of glycemia. Diabet Med 1996; 13: 55
36. Horowitz M, Wishart JM, Jones KL et al. Gastric emptying in diabetes: An overview. Diabet Med 1996; 13: S16-22
37. Phillips WT, Schwartz JG, McMahan CA. Reduced postprandial blood glucose levels in recently diagnosed non-insulin-dependent diabetics secondary to pharmacologically induced delayed gastric emptying. Dig Dis Sci 1993; 38: 51-8
38. Schwartz JG, Guan D, Green GM et al. Treatment with an oral proteinase inhibitor slows gastric emptying and acutely reduces glucose and insulin levels alter a liquid meal in type II diabetic patients. Diabetes Care 1994; 17: 255-62
39. Willms B, Werner J, Holst J, Creutzfeldt W et al. Gastric emptying, glucose response and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide 1 (GLP-I) amide in type 2 (non-insulin dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32
40. Ishii M, Nakamura T, Kasai F et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17: 901-3
41. Jones KL, Horowitz M, Wishart MJ et al. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med 1995; 36: 2220-8
42. Jones KL, Horowitz M, Carney BI et al. Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Gut 1996; 38: 310-5
43. Schwartz JG, McMahan CA, Green GM et al. Gastric emptying in Mexican Americans compared to non-Hispanic whites. Dig Dis Sci 1995; 40: 624-30
44. Corvilain B, Abramowicz M, Fery F et al. Effect of short-term starvation on gastric emptying in humans: Relationship to oral glucose tolerance. Am J Physiol 1995; 269: G512-7
45. Horowitz M, Edelbroek MA, Wishart JM et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-62
46. Liddle RA, Rushakoff RJ, Morita ET et al. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 1988; 81: 1657-81
47. Phillips WT, Schwartz JG. Decelerating gastric emptying: Therapeutic possibilities in type 2 diabetes. Diabet Med 1996; 13:S44-8
48. Hill AJ, Peikin SR, Ryan CA et al. Oral administration of proteinase inhibitor II from potatoes reduces energy intake in man. Physiol Behav 1990; 48: 241-6
49. Nauck M. Therapeutic potential of glucagon-like peptide in type 2 diabetes. Diabet Med 1996; 13: S39-43
50. Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-I (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73
51. Nathan DM, Schreiber E, Fogel H et al. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270-6
52. Gutniak M, Orskov C, Hoist JJ et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)-amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-22
53. Dupre J, Behme MT, Hramiak IM et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44: 626-30
54. Orskov C, Hoist JJ, Nielsen OV. Effect of truncated glucagon-like peptide 1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and nonantral stomach. Endocrinol 1988; 123: 2009-13
55. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28:704-7
56. Kawai K, Suzuki S, Ohashi S et al. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 1989; 124: 1768-73
57. Kreymann B, Williams G, Ghatei MA et al. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2: 1300-4
58. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1(7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7
59. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72
60. Moyses C, Young A, Kolterman O. Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabet Med 1996; 13: S34-8
61. Castillo MJ, Sheen AJ, Lefebre PJ. Amylin/islet amyloid polypeptide: Biochemistry, physiology, patho-physiology. Diabet Metab 1995; 21: 3-25
62. Koda JE, Fineman MS, Kolterman OG et al. 24 hour plasma amylin levels are elevated in IGT subjects vs. normal controls. Diabetes 1995; 44 (suppl. 1): 238A
63. Cooper GJ, Leighton B, Dimitriadis GD et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85: 7763-6
64. Ogawa A, Harris V, McCorkle SK et al. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990; 85: 973-6
65. Young AA. Amylin regulation of fuel metabolism. J Cell Biochem 1994; 55: 12-8
66. Gedulin BR, Jodka CM, Green DE et al. Potency and effectiveness of amylin and five gut peptides on gastric emptying in rats. Diabetes 1995; 44 (suppl. 1); 133A
67. Tallev NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications. Aliment Pharmacol Ther 1992; 6: 273-89
68. Horowitz M, Edelbroek M, Fraser R et al. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol 1991; 26: 673-84
69. Fraser RJ, Horowitz M, Maddox AF et al. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis - effects of cisapride. Gut 1994; 35: 172-8
70. Janssens J, Peeters TL, Vantrappen G, Tack J et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 1028-31
71. Parkman HP, Pagano AP, Ryan JP. Erythromycin inhibits rabbit pyloric smooth muscle through neuronal motilin receptors. Gastroenterology 1996; 111: 682-90
72. Horowitz M, Maddox A, Harding PE et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899-907
73. Rees WD, Leigh RJ, Christofides ND et al. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology 1982; 83: 575-80
74. Horowitz M, Cunningham KM, Wishart JM et al. The effect of short-term dietary supplementation with glucose on gastric emptying of glucose and fructose and oral glucose tolerance in normal subjects. Diabetologia 1996; 39: 481-6
75. Abell TL, Camilleri M, DiMagno EP et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616-20
76. McHugh S, Lico S, Diamant NE. Cisapride vs. metoclopramide. An acute study in diabetic gastroparesis. Dig Dis Sci 1992; 37: 997-1001
77. Cooke HJ, Carey HV. Pharmacological analysis of 5-hydroxytryptamine actions on guinea-pig ileal mucosa. Eur J Pharmacol 1985; 111: 329-37
78. Catnach SM, Ballinger AB, Stevens M et al. Erythromycin induces supranormal gallbladder contraction in diabetic autonomie neuropathy. Gut 1993; 34: 1123-7
79. Chey WD, Kim M, Hasler WL et al. Hyperglycemia alters perception of rectal distention and blunts the rectoanal inhibitory reflex in healthy volunteers. Gastroenterology 1995; 108: 1700-8
80. Carlson RG, Hocking MP, Sninsky CA et al. Erythromycin acts through a cholinergic pathway to improve canine-delayed gastric emptying following vagotomy and Roux-Y antrectomy. J Surg Res 1991; 50: 494-8
81. Battle WM, Cohen JD, Snape WJ. Disorders of colonic motility in patients with diabetes mellitus. Yale J Biol Med 1983; 56: 277-83
82. Mansi C, Savarino V, Vigneri S et al. Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: A double-blind cross-over study. Aliment Pharmacol Ther 1995; 9: 185-9
83. Passaretti S, Tosi T, Tittobello A. Effect of levosulpiride on gastric emptying in healthy volunteers. Clin Tri J 1990; 27: 100-2
84. Pustorino S, Ianni G, Migliorato A. Effects of levosulpiride on the kinetics of gallbladder emptying and duodenal-gastric reflux in patients with idiopathic alkaline gastritis. Curr Ther Res 1989; 46: 1110-8
85. Ogbonnaya KI, Arem R. Diabetic diarrhea: Pathophysiology, diagnosis and management. Arch Intern Med 1990; 150: 262-7
86. Huppin H. Review: Ioperanude - a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1989; 1: 179-190
87. Heel RC, Brogden RN, Speight TM et al. Loperamide: A review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978; 15: 33-52
88. Loo FD, Dodds WJ, Soergel KH et al. Multipeaked esophageal peristaltic pressure waves in patients with diabetic neuropathy. Gastroenterology 1985; 88: 485-91
89. Fedorok RM, Field M, Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med 1985; 102: 197-9
90. Schiller LR, Santa Ana CA et al. Studies on the antidiarrheal action of clonidine. Effects on motility and intestinal absorption. Gastroenterology 1985; 89: 982-8
91. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461-71
92. Moller N, Petrany G, Cassidy D et al. Effects of the somatostatin analogue SMS 201-995 (sandostatin) on month-to-caecum transit time and absorption of fat and carbohydrates in normal man. Clin Sci 1988; 75: 345-50
93. Witt K, Pedersen NT. The long acting somatostatin analogue SMS 201-995 causes malabsorption. Scand J Gastroentcrol 1989; 24: 1248-52
94. Compean DG, Jimenez JF, De La Garza FG. Octreotide therapy of large-volume refractory AIDS associated diarrhea: A randomized clinical trial. AIDS 1994; 8: 1563-7
95. Baillie Johnson HR. Octreotide in the management of treatment-related diarrhea. Anticancer Drugs 1996; 1: 11-5
96. Farthing MJ. The role of somatostatin analogues in the treatment of refractory diarrhoea. Digestion 1996; 1: 107-13
97. Toskes PP. Hope for the treatment of intestinal scleroderma. N Engl J Med 1991; 21: 1508
98. Chen JDZ, Lin ZY, Edmunds MC et al. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig Dis Sci 1998; 43: 80-9
99. Moser AJ, Abedin MZ, Ciurgiu DI et al. Octreotide promotes gallbladder absorption in prairie dogs: A potential cause of gallstones. Gastroenterology 1995; 108: 1547-55
100. Redfern JS, Fortuner W. Octreotide-associated biliary tract dysfunction and gallstone formation: Pathophysiology and management. Am J Gastroenterol 1995; 90: 1042-52
101. Tauber JP, Poncet MF, Harris AG et al. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. J Clin Endocrinol Metab 1995; 80: 3262-6
102. De Santis A, Attili AF, Corradini SG et al. Gallstones and diabetes: A case-control study in a free-living population sample. Hepatology 1997; 25: 787-90
103. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med 1983; 98: 378-84
104. Taub S, Mariani A. Gastrointestinal manifestations of diabetes mellitus. Diabetes Care 1979; 2: 437-64
105. Kaye SA, Lim SG, Taylor M et al. Small bowel bacterial overgrowth in systemic sclerosis: Detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995; 34: 265-9
106. Gaber AO, Oxley D, Karas J, Cardoso S et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis Sci 1991; 9: 437-43
107. Hathaway DK, Abell T, Cardoso S et al. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 1994; 57: 816-22
108. Aridge D, Reese J, Niehoff M et al. Effect of successful renal and segmental pancreatic transplantation on peripheral and autonomic neuropathy. Transplant Proc 1991; 23: 1670-1
109. Nowak TV, Roza AM, Weisbruch JP et al. Accelerated gastric emptying in diabetic rodents: Effect of insulin treatment and pancreas transplantation. J Lab Clin Med 1994; 123: 110-6
110. Reissell E, Taskinen MR, Orko R et al. Increased volume of gastric contents in diabetic patients undergoing renal transplantation: Lack of effect with cisapride. Acta Anaesthesiol Scand 1992; 36: 736-40
111. Murat A, Pouliquen B, Cantarovich D et al. Gastric emptying improvement after simultaneous segmental pancreas and kidney transplantation. Transplant Proc 1992; 24: 855
112. Kelly KA, La Force RC. Role of gastric pacesetter potential defined by electrical pacing. Am J Physiol 1972; 222: 588-94
113. The GMS study group. Second report of a multicenter study on electrical stimulation for the treatment of gastroparesis. Gut 1996; 39: A103
114. The GMS study group. Report of a multicenter study on electrical stimulation for the treatment of gastroparesis (abstr.). Gastroenterology 1997; 112: A735
115. McCallum RW, Chen JZ, Lin Z et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114: 456-61
116. Wald A, Tunuguntla AK. Anorectal sensorimotor dysfunction in fecal incontinence and diabetes mellitus. Modification with biofeedback therapy. N Engl J Med 1994; 310: 1282-7